Abstract
Growth retardation is common in children with chronic renal failure (CRF) and after renal transplantation (Tx). For this reason we treated 9 children (3 on conservative treatment, CT; 3 on dialysis, D; and 3 Tx), aged 1.6 to 14.0 (x±sd; 8.1 ± 4.3) years, with twice daily subcutaneous injections of growth - hormone-releasing analogue, GHRH (1-29)NH2 Serono at a mean dose of 26±7 ug/kg/day, during 2 to 6 months. Mean serum urea and creatinine remained stable, although in CT patients serum creatinine increased moderately. Before treatment, mean bone age was 5.2 ± 3.1 years, height SDS -2.2±0.6 and growth velocity 4.5±2.9 cm/year (-2.3±2.0 DS for chronological age). Mean nocturnal spontaneous growth hormone (xGH) was 3.3±1.6 ng/ml, smooth line 1.6±0.9 ng/ml, amplitude 5.4±2.6 ng/ml, number of peaks 3.8±1.3 and growth hormone (GH) response to GHRH test (1 ug/kg IV) 61.7±52.5 ng/ml. Five patients, all 3 on CT included, increased the height velocity from 3.8±1.6 to 8.0±2.6 cm/year. The peak GH response to GHRH was significantly higher in the group of growth non-responders than the responders (p<0.05). Conclusion: GHRH treatment increased growth velocity in 55% of our patients. All CT patients had a worthwhile response to therapy: height velocity increased by more than 2 cm/year. Growth response to GHRH was lower when GH response to GHRH test was high, suggesting peripheral resistance to the biological action of GH.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pasqualini, T., Moyano, S., Gutma, R. et al. 25 TREATMENT OF CHRONIC RENAL FAILURE WITH GROWTH-HORMONE-RELEASING HORMONE. Pediatr Res 36, 682 (1994). https://doi.org/10.1203/00006450-199411000-00083
Issue Date:
DOI: https://doi.org/10.1203/00006450-199411000-00083